Teva announces austedo® xr (deutetrabenazine) extended-release tablets now u.s. fda approved as a one pill, once-daily treatment option for clinically therapeutic doses (24–48 mg/day)

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced that the u.s. food and drug administration (fda) has approved austedo xr as a one pill, once-daily treatment option, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults for td and hd chorea. “since our launch of austedo® in 2017, we have been committed to helping people living with td and hd chorea treat.
TEVA Ratings Summary
TEVA Quant Ranking